Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × balstilimab × Other solid neoplasm × Clear all

Phase

Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Resectable MMR-deficient Solid Tumors 1

Interventions

pembrolizumab 3 Pemetrexed 2 Drug Therapy 2 Cisplatin 2 toripalimab 1 tislelizumab 1 spartalizumab 1 sintilimab 1 penpulimab 1 nintedanib 1 camrelizumab 1 balstilimab 1 atezolizumab 1 anlotinib 1 Vincristine 1 Topotecan 1 Sentinel Lymph Node Biopsy 1 Platinum Compounds 1 Melphalan 1 Inosine 1 Injections 1 Indocyanine Green 1 Immunotherapy 1 Hyperthermia, Induced 1 Etoposide 1 Cryotherapy 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06279130 2026-03-05

NEOASIS

The Netherlands Cancer Institute

Phase 2/3 Recruiting

Other solid neoplasm

Resectable MMR-deficient Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡